roco glp 1 GLP-ONE + Receptor Activator 1 and CB2 receptors to help reduce appetite The Complete Guide to Weight

In the study, only a quarter of the patients remained on any GLP-1RA one year after starting, with roughly 1 in 5 patients transitioning to a different GLP-1RA during that period

This may also increase long-term health risks

Dual peptides for the treatment of obesity Tirzepatide, a novel dual GIP and GLP-1RA, offers significant insights into its mechanism of action, therapeutic benefits, and clinical applications for the management of T2D and obesity in general practice

All of those 3 things are done by GLP-1 and this is a version of GLP-1

doi: 10.3233/JAD-190156 [DOI] [PubMed] [Google Scholar] 10

N Engl J Med 390(15):13941407 Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ et al (2024) Semaglutide and NT-proBNP in obesity-related HFpEF